Community acquired and post-transfusion hepatitis C  is there a difference? by Qureshi, A R et al.
eCommons@AKU
Section of Gastroenterology Department of Medicine
January 1996
Community acquired and post-transfusion
hepatitis C "is there a difference?"
A R. Qureshi
Aga Khan University
S Hamid
Aga Khan University, saeed.hamid@aku.edu
W Jafri
Aga Khan University, wasim.jafri@aku.edu
F Ejaz
Aga Khan University
H Shah
Aga Khan University, hasnain.alishah@aku.edu
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_gastroenterol
Part of the Gastroenterology Commons
Recommended Citation
Qureshi, A. R., Hamid, S., Jafri, W., Ejaz, F., Shah, H., Abbas, Z., Abid, S., Khan, H. (1996). Community acquired and post-transfusion
hepatitis C "is there a difference?". Journal of Pakistan Medical Association, 46(1), 9-11.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/170
Authors
A R. Qureshi, S Hamid, W Jafri, F Ejaz, H Shah, Z Abbas, S Abid, and H Khan
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol/170
Community Acquired and Post-Transfusion Hepatitis C ”Is
There a Difference?”
Pages with reference to book, From 9 To 11 
A. R. Qureshi, S. Hamid, W. Jafri, H. Shah, Z. Abbas, S. Abid, H. Khan ( Departments of Medicine, The Aga Khati
University Hospital, Karachi. ) 
F. Ejaz ( Departments of Pathology, The Aga Khati University Hospital, Karachi. ) 
Abstract 
We analyzed 77 consecutive hepatitis C antibody positive patients to compare the history, laboratory
data and histological features of community acquired (CA) and post-transfusion (PT) hepatitis C.
Forty-six patients had “CA” and 31 “PT” hepatitis C. Mean age in both groups was same (45.67 vs 46
years). Male to female ratio was 2:1 in the CA group and 1:2.4 in the PT group. Mean duration between
jaundice and first presentation was 8.9 years in the CA group and the mean duration between
transfusion and first presentation was 9.8 years in PT group. No significant difference was found
between two groups in the laboratory data. Liver biopsy was done in 32 patients (19 CA and 13 PT
group). Mean histological score for disease activity was 9.3 in both groups, although more (68%)
patients in the CA group had cirrhosis with chronic active hepatitis, (CAH) as compared to the PT
(54%) group. Hepatitis C is an important cause of CA hepatitis. PT hepatitis C is more common in
females because of increased likelihood of receiving transfusion for obstetric and gynaecological
reasons. There is no significant difference in the laboratory and histological features between CA and
PT hepatitis C (JPMA 46:9, 1996).
Introduction 
NonA NonB hepatitis was first recognised in 19741. In mid 70’s, it was demonstrated that 5-12% of
cases developed hepatitis after transfusion of hepatitis B surface antigen negative blood. Among these
patients, 90% were diagnosed to have Non A Non B hepatitis2,3. The causative agent for tile great
majority of cases of Non A Non B hepatitis was discovered recently and named Hepatitis C virus
(HCV)4. The subsequent development ofantibody tests forHCV have made possible the easy diagnosis
and the study of this infection5. Now hepatitis C is recognized to be a common disease with a world-
wide distribution and accounts for more than 90% of post-transfusion hepatitis6. The current estimated
incidence of acute infection a.mong transfusion recipients is from five to ten percent7.
Although, initially regarded mainly as a blood-borne infection, due to the similarities with hepatitis B, a
significant proportion of patients with HCV infection have no known risk factors for disease
transmission8. This “community acquired HCV infection” is thought to differ from post-transfusion
HCV (PT- HCV) in being more slowly progressive and to perhaps effect an older population9.
Chronicity is a common feature of both forms of hepatitis C and chronic hepatitis develops in 50% of
these patients and cirrhosis in 20%9-11
This study compares the features of communityacqu.ired and post transfusion hepatitis C ith respect to
demographic data clinical presentation laboratozy data and histological findings.
Patients and Methods 
Seventy-seven consecutive antibody positive patients were analyzed. They were seen either at their
outpatient visit or during their admission. A profonna filled for each patient, included demographic
data, principal symptom on first presentation, histozy of blood transfusion and post transfusion
jaundice and past history of jaundice. Also recorded were the risk factors for hepatitis C. like history of
drug abuse, I.V injections, occupational exposure or sexual exposure to prostitutes. Laboratory data
included a complete blood count, liver function test, hepatitis serology and histological features where
available. Patients with a clear history of blood transfusion were included in the post-transfusion
groups and those without as “community acquired hepatitis C”. Also included in this group were
patients with a history of extra marital sexual contact or I.V. drug abuse.
The results are expressed in percentage incidence and rnean±SD. Chi-square tests were used to identify
significant differences among the groups. P value <(105 are considered to be statistically significant.
Results 
Offl patients, 46 had CA hepatitis C while 31 had post-transfusion hepatitis C. This was based on the
history of transfusion in the past.
Table 1 compares the demographic data of the two groups. A significantly higher proportion of females
had post transfusion hepatitis C (p<0.005).
Appmximately 60% of patients from both groups were out patients and the remaining in-patients. The
major symptoms at first presentation are listed in Table II.
About 35% patients inboth groups had general constitutional symptoms at
first presentation while 10-15% in both groups were diagnosed incidentally i.e., either at surgery or
they presented with some other problems and on testing were found to have an elevated
aminotransferase level and later found to be HCV antibody positive.
Twenty-seven patients had a definite past history of jaundice in the “CA” group and the range of
duration between jaundice to first presentation was 1-30 years and the mean duration between jaundice
and presentation was 8.9 years. Forty-one percent patients had no prior history ofjaundice and among
these patients, 5 had a history of contact with a patient of chronic liver disease or hepatitis in the
immediate family and3 (6.52%) had a history of extra marital sexual contact. There were no dntg
addicts in this cohort.
Thirty-one patients had a history of blood transfusion in the past and the duration between transfusion
and first presentation was 1-27 years and the mean duration was 9.8 years. Only 6 had a history ofpost-
transfusionjaundice and all of these patients had jaundice within first 3 months of blood transfusion.
A comparison of laboratory data is shown in Table III.
Minimal level of hacmoglobin, platelet count and albuminand the maximum level of bilirubin, SGPT,
SOOT, alkaline phosphatase, globulin and prothrombin time are analyzed for each patient. All these
figures are expressed as mean±standard deviation.
Hepatitis B surface antigen and HC\\’ antibody were done in all and both were positive in only three
patients, indicating HB V/HCV co-infection. Hepatitis B core antibody IgG was done in 58 patients and
was found reactive in 28 patients.
Liver biopsy was done in 32 patients. Nineteen had CA hepatitis C and 13 had PT hepatitis C. The
histological features were-compared and histological activity index12 was calculated and compared in
both groups. The comparison of histological features is shown in Table IV.
Discussion 
This study raises several important issues related in patients with chronic HCV infection. In majority of
patients like in other studies, the mode of transmission of HCV is not clear13. Agents possibly
implicated in this inapparent transmission of HCV are parental injections with unsterile needles as is
common practice in our countiy, arthropod vectors like mosquitoes, sexual orhousehold exposure etc.
However, there is no conclusive proof so farforany of these factors and further studies are required in
this area.
There was no difference in the meanage of presenlation betweenthetwo groups. Aithougha
numberofpatients inboth groups did not have a history ofjaundice, the mean duration between the onset
of jaundice to presentation was similar in both groups at around 9 years. Both these figures suggest that
CA-HCV may notbe as indolent a disease as thought to be and does not seem to have a very different
natural history as compared to PT-HCV9. The mean duration to presentation at 9 years also suggests
that in our group of patients with CA-HCV, exposure is likely to have occurred in the late 20’s orearly
30’s and that early childhood exposure seems unlikely, given that the mean age of presentation in our
patients is around 46 years.
Majority of patients with PT-HCV were females. Most of these transfusions were given for obstetric or
gynaecological causes. The facilities of screening of blood for HCV are available at only few centres in
our country, therefore, most transfused blood is unscreened for HCV.
In sumnary, liver disease caused by chronic HCV infection is an important problem in our setting and
in the majority of these patients the route of transmission is not known. Until this is clarified, common
sense precautions like the use of sterile needles and effective protection against sexual transmission are
needed. Blood should be screened for HCV and the need for a transfusion should always be very
carefully assessed, particularly so in places where HCV testing is not yet available.
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